PDCD1 and melanoma: Recent clinical data from monoclonal antibody blockers of the PD-1/PD-L1 pathway indicate that such drugs restore the anti-tumor immunity, with the potential to produce durable clinical responses for patients.[4–6] Herein, we present a case report of a patient with melanoma and a sequence of treatments that lead to disease regression over the past 5 years.